Nanobac Announces European Heart Journal Publication of Association Between Calcifying...

Nanobac Announces European Heart Journal Publication of Association Between Calcifying Nanoparticles and Aortic Stenosis

TAMPA, Fla.--(Business Wire)--Nanobac Pharmaceuticals Inc. (OTCBB:NNBP) ("Nanobac" or "the
Company") announces the multicenter publication of independent
research which reports an association between calcifying nanoparticles
(CNPs) and aortic stenosis. Aortic stenosis represents the most
frequent cause of heart valve replacement (Bratos-Perez et al,
European Heart Journal Advance Access, doi:10.1093/eurheartj/ehm592).

The authors contend: "For the first time, this study shows that
CNP could be causally related to aortic stenosis in humans. We suggest
that CNPs colonize the aortic valve, provoking an inflammatory
response, resulting in valve calcification via two distinct
mechanisms: directly given their capacity to precipitate calcium in
the shape of apatite crystals, at physiological calcium and phosphate
concentrations, and indirectly by activating the inflammatory
pathways."

"Although the finding of nanoparticles in such a significant
number of patients with calcific aortic stenosis does not establish
that such particles influence this condition, the question of such
influence now `begs' to be answered," said Richard A Berger MD.FACC.,
Asst Professor of Cardiology University of Miami Medical School.

Diagnosis for the presence of CNPs in these patients may be of
help in learning more about this frequently fatal disease. Aortic
valve stenosis affects 2-8% of adults over the age of 65, and is the
number one indication for surgical valve replacement in the US and
Europe. Nanobac has developed proprietary diagnostics to identify
patients that could benefit from therapy for preventing the advance of
this disease to stages needing surgery. Valve replacement surgery is
currently the only curative treatment, but it is limited to patients
of younger age, better health and has the limitation of the need for
anticoagulant therapy not suitable for all patients. Nanobac also has
therapies that treat CNPs, and could eliminate the need for surgery.

Nanobac Pharmaceuticals Inc. is headquartered in Tampa, Florida.
For more information, visit our website at: http://www.nanobac.com.

Investors are cautioned that certain statements in this document,
some statements in periodic press releases and some oral statements of
Nanobac Pharmaceuticals, Inc. officials are "Forward-Looking
Statements" within the meaning of the Private Securities Litigation
Reform Act of 1995 (the "Act"). Forward-Looking statements include
statements which are predictive in nature, which depend upon or refer
to future events or conditions, which include words such as
"believes," "anticipates," "intends," "plans," "expects," and similar
expressions. In addition, any statements concerning future financial
performance (including future revenues, earnings or growth rates),
ongoing business strategies or prospects, and possible future Nanobac
Pharmaceuticals, Inc. actions, which may be provided by management,
are also forward-looking statements as defined by the Act.
Forward-Looking statements involve known and unknown risks,
uncertainties, and other factors which may cause the actual results,
performance or achievements of the Company to materially differ from
any future results, performance or achievements expressed or implied
by such forward-looking statements and to vary significantly from
reporting period to reporting period. Although management believes
that the assumptions will, in fact, prove to be correct or that actual
future results will not be different from the expectations expressed
in this report. These statements are not guarantees of future
performance and Nanobac Pharmaceuticals, Inc. has no specific
intention to update these statements.

Nanobac Pharmaceuticals Inc., Tampa
Brady Millican, 813-264-2241
or
Redwood Consultants
Jens Dalsgaard, 415-884-0348

Copyright Business Wire 2008